Weekly Carboplatin plus Paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study
Taxanes are a mainstay in the treatment of metastatic breast cancer ( mBC ). Combination chemotherapy, including Platinum-taxens doublets, can improve tumor responses and progression-free survival ( PFS ), but is associated with more toxicities and an uncertain benefit in terms of overall survival ( OS ).
Researchers have performed a retrospective study on 274 consecutive patients with metastatic breast cancer treated at the Division of Medical Oncology of Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy, during the decade 2007-2016 with the combination of Carboplatin AUC 2 plus Paclitaxel 80 mg/m2, both given on days 1 and 8 in every 21-day cycle.
264 patients were evaluable for treatment safety and activity.
The objective response rate ( ORR ) was 44.7%. Median progression-free survival and overall survival were 8.6 and 23.7 months, respectively.
Triple-negative breast cancer ( TNBC ) patients had significantly lower progression-free survival and overall survival times compared to other biology groups.
At multivariable analysis, previous exposure to taxanes, HR-positive HER2-negative biology, a higher number of metastatic sites, and de novo metastatic disease at diagnosis were associated with reduced progression-free survival, while receiving maintenance therapy correlated with improved progression-free survival.
Overall, the treatment was quite well tolerated, with 10.2% of patients discontinuing one or both drugs because of adverse events.
G3-G4 neutropenia occurred in 16.8% of patients, while the incidence of febrile neutropenia was 2.3%.
In conclusion, weekly Carboplatin-Paclitaxel regimen is active and well tolerated in metastatic breast cancer treatment.
Prospective studies should be conducted to compare its efficacy and tolerability with standard single-agent Paclitaxel or Docetaxel treatment schedules, as well as with more recent combination regimens. ( Xagena )
Vernieri C et al, Breast Cancer Res Treat 2017; [Epub ahead of print
Tukysa for the treatment of patients with locally advanced or metastatic HER2-positive breast cancer, approved in European Union
The European Commission ( EC ) has granted marketing authorization for Tukysa ( Tucatinib ) in combination with Trastuzumab and...
Dalpiciclib versus placebo plus Fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy
Dalpiciclib, a novel CDK4/6 inhibitor, as monotherapy has demonstrated tolerability and preliminary antitumor activity in pretreated HR+/HER2− advanced breast cancer...
FDA has approved Phesgo, a combination of Pertuzumab, Trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer
The Food and Drug Administration ( FDA ) has approved a new fixed-dose combination of Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf ( Phesgo...
MONARCH 2: subgroup analysis of patients receiving Abemaciclib + Fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer
In MONARCH 2 ( M2 ), Abemaciclib ( Verzenios ), an oral selective cyclin dependent kinase 4 & 6 inhibitor,...
PARSIFAL trial: Palbociclib in combination with Fulvestrant or Letrozole in endocrine-sensitive patients with ER+/HER2- metastatic breast cancer
The CDK4/6 inhibitor Palbociclib ( Ibrance ) in combination with Letrozole ( Femara ) has become a standard first-line treatment...
Genome-wide transcriptional analysis has identified a unique subset of androgen receptor (AR)+, estrogen receptor ( ER ) / progesterone receptor...
monarchE trial: Abemaciclib given with endocrine therapy has shown improvement compared to endocrine therapy alone in people whose HR+ HER2- early breast cancer is at a high risk of recurrence
Abemaciclib ( Verzenio ) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free...
IPATential150 study: Ipatasertib in combination with Abiraterone and Prednisone / Prednisolone met its co-primary endpoint of radiographic progression free survival in patients with PTEN loss tumours
Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...
European Commission has approved Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer
The European Commission has approved Tecentriq ( Atezolizumab ) plus chemotherapy ( Abraxane [ Paclitaxel protein-bound particles for injectable suspension...
FDA has warned about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer
The FDA ( U.S. Food and Drug Administration ) has warned that Ibrance ( Palbociclib ), Kisqali ( Ribociclib ),...